{
  "relationships": [
    {
      "entity1": "Almorexant",
      "entity2": "orexin system",
      "relationship": "inhibits",
      "evidence_text": "Almorexant is now mainly used as a commercial specific inhibitor of the orexin system in animal studies due to safety issues.",
      "confidence": 0.9,
      "pmid": "35972717"
    },
    {
      "entity1": "Orexin-A",
      "entity2": "HCRTR1",
      "relationship": "binds_to",
      "evidence_text": "the hypocretins/orexins are two excitatory neuropeptides... that are the endogenous ligands for two G-protein-coupled receptors, HCRTR1/OX1R and HCRTR2/OX2R.",
      "confidence": 1.0,
      "pmid": "34052813"
    },
    {
      "entity1": "Orexin-A",
      "entity2": "HCRTR2",
      "relationship": "binds_to",
      "evidence_text": "the hypocretins/orexins are two excitatory neuropeptides... that are the endogenous ligands for two G-protein-coupled receptors, HCRTR1/OX1R and HCRTR2/OX2R.",
      "confidence": 1.0,
      "pmid": "34052813"
    },
    {
      "entity1": "orexin system",
      "entity2": "Alzheimer's disease",
      "relationship": "associated_with",
      "evidence_text": "Dysregulation of the orexin system occurs in aging and AD, positioning ORAs as advantageous for these populations.",
      "confidence": 0.8,
      "pmid": "37708433"
    },
    {
      "entity1": "orexin system",
      "entity2": "Alzheimer's disease",
      "relationship": "associated_with",
      "evidence_text": "Given the high prevalence of sleep disturbances in Alzheimer's disease (AD) and their reported involvement in AD pathophysiology, the orexin system is hypothesized to contribute to the disease pathogenesis.",
      "confidence": 0.85,
      "pmid": "39365407"
    },
    {
      "entity1": "SORA1",
      "entity2": "anxiety",
      "relationship": "regulates",
      "evidence_text": "SORA1 may be promising for the treatment of anxiety and drug addiction.",
      "confidence": 0.7,
      "pmid": "31782044"
    },
    {
      "entity1": "Orexin-A",
      "entity2": "HCRTR1",
      "relationship": "inhibits",
      "evidence_text": "Overall, it was concluded that OXA exerts neuroprotective effect ... by Inhibiting OX1R-mediated NF-\u03baB, MAPK/ERK and MAPK/p38 signaling pathways.",
      "confidence": 0.95,
      "pmid": "34358627"
    },
    {
      "entity1": "Orexin-A",
      "entity2": "NF-\u03baB",
      "relationship": "inhibits",
      "evidence_text": "Overall, it was concluded that OXA exerts neuroprotective effect ... by Inhibiting OX1R-mediated NF-\u03baB, MAPK/ERK and MAPK/p38 signaling pathways.",
      "confidence": 0.9,
      "pmid": "34358627"
    },
    {
      "entity1": "TAK-861",
      "entity2": "OX2R",
      "relationship": "activates",
      "evidence_text": "TAK-861 ... activates OX2R with a half-maximal effective concentration of 2.5\u00a0nM.",
      "confidence": 0.98,
      "pmid": "39242684"
    },
    {
      "entity1": "TAK-994",
      "entity2": "OX2R",
      "relationship": "activates",
      "evidence_text": "TAK-994, an oral orexin receptor 2-selective agonist, in patients with narcolepsy type 1.",
      "confidence": 0.95,
      "pmid": "37494485"
    },
    {
      "entity1": "MSZRD",
      "entity2": "Orexin-A",
      "relationship": "inhibits",
      "evidence_text": "MSZRD significantly downregulated the serum Orexin-A content in insomnia mice.",
      "confidence": 0.9,
      "pmid": "34509822"
    },
    {
      "entity1": "MSZRD",
      "entity2": "OX2R",
      "relationship": "inhibits",
      "evidence_text": "MSZRD significantly downregulated ... hypothalamic OX2R expression.",
      "confidence": 0.9,
      "pmid": "34509822"
    },
    {
      "entity1": "almorexant",
      "entity2": "orexin receptors",
      "relationship": "inhibits",
      "evidence_text": "injected intraperitoneally with almorexant, a dual orexin receptor antagonist (DORA)",
      "confidence": 0.95,
      "pmid": "39047304"
    },
    {
      "entity1": "almorexant",
      "entity2": "A\u03b2 deposition",
      "relationship": "inhibits",
      "evidence_text": "The application of almorexant can increase the total sleep time of sleep-deprived mice and reduce cognitive impairment and A\u03b2 deposition",
      "confidence": 0.92,
      "pmid": "39047304"
    },
    {
      "entity1": "almorexant",
      "entity2": "Aquaporin-4 polarity",
      "relationship": "associated_with",
      "evidence_text": "which is related to the improvement in Aquaporin-4 polarity",
      "confidence": 0.85,
      "pmid": "39047304"
    },
    {
      "entity1": "sleep deprivation",
      "entity2": "A\u03b2 deposition",
      "relationship": "activates",
      "evidence_text": "sleep deprivation aggravated learning and memory impairment and increased brain \u03b2-amyloid (A\u03b2) deposition in mice with AD",
      "confidence": 0.9,
      "pmid": "39047304"
    },
    {
      "entity1": "orexin",
      "entity2": "OX1R",
      "relationship": "activates",
      "evidence_text": "Orexins ... bind and activating two G-protein-coupled receptors (GPCRs), orexin receptor type 1 (OX1R) and type 2 (OX2R)",
      "confidence": 0.96,
      "pmid": "30002617"
    },
    {
      "entity1": "orexin",
      "entity2": "OX2R",
      "relationship": "activates",
      "evidence_text": "Orexins ... bind and activating two G-protein-coupled receptors (GPCRs), orexin receptor type 1 (OX1R) and type 2 (OX2R)",
      "confidence": 0.96,
      "pmid": "30002617"
    },
    {
      "entity1": "orexin",
      "entity2": "OX1R",
      "relationship": "activates",
      "evidence_text": "Orexin enhances learning and memory as well as reward, stress, seizures, and epilepsy, partly through OX1Rs",
      "confidence": 0.88,
      "pmid": "35180935"
    },
    {
      "entity1": "5-HT1AR",
      "entity2": "OX1R",
      "relationship": "binds_to",
      "evidence_text": "5-HT1AR and OX1R form constitutive heterodimers",
      "confidence": 0.94,
      "pmid": "35338110"
    },
    {
      "entity1": "orexin system",
      "entity2": "hypertension",
      "relationship": "activates",
      "evidence_text": "hyperactivity of the orexin system contributes to hypertension",
      "confidence": 0.9,
      "pmid": "28349223"
    },
    {
      "entity1": "20d",
      "entity2": "OX2R",
      "relationship": "activates",
      "evidence_text": "20d and 28d showed full agonist activity against OX",
      "confidence": 0.89,
      "pmid": "36690040"
    },
    {
      "entity1": "28d",
      "entity2": "OX2R",
      "relationship": "activates",
      "evidence_text": "20d and 28d showed full agonist activity against OX",
      "confidence": 0.89,
      "pmid": "36690040"
    },
    {
      "entity1": "ORN0829",
      "entity2": "OX1R",
      "relationship": "inhibits",
      "evidence_text": "potent dual orexin 1/2 receptor antagonist for the treatment of insomnia",
      "confidence": 0.93,
      "pmid": "32482533"
    },
    {
      "entity1": "ORN0829",
      "entity2": "OX2R",
      "relationship": "inhibits",
      "evidence_text": "potent dual orexin 1/2 receptor antagonist for the treatment of insomnia",
      "confidence": 0.93,
      "pmid": "32482533"
    },
    {
      "entity1": "OX2R antagonist",
      "entity2": "OX2R",
      "relationship": "inhibits",
      "evidence_text": "dual orexin receptor antagonist suvorexant",
      "confidence": 0.9,
      "pmid": "37553894"
    },
    {
      "entity1": "OX2R antagonist",
      "entity2": "cognitive performance",
      "relationship": "associated_with",
      "evidence_text": "Orexin 2 receptor antagonism ... improves ... cognitive performance in tau transgenic mice",
      "confidence": 0.88,
      "pmid": "37553894"
    },
    {
      "entity1": "OXA",
      "entity2": "OX1R",
      "relationship": "binds_to",
      "evidence_text": "Both OXA and OXB peptides bind to two G-coupled receptors, orexin-1 (OX1R) and orexin-2 (OX2R) receptor, though with different binding affinity.",
      "confidence": 0.96,
      "pmid": "29496265"
    },
    {
      "entity1": "OXA",
      "entity2": "OX2R",
      "relationship": "binds_to",
      "evidence_text": "Both OXA and OXB peptides bind to two G-coupled receptors, orexin-1 (OX1R) and orexin-2 (OX2R) receptor, though with different binding affinity.",
      "confidence": 0.96,
      "pmid": "29496265"
    },
    {
      "entity1": "OXB",
      "entity2": "OX1R",
      "relationship": "binds_to",
      "evidence_text": "Both OXA and OXB peptides bind to two G-coupled receptors, orexin-1 (OX1R) and orexin-2 (OX2R) receptor, though with different binding affinity.",
      "confidence": 0.96,
      "pmid": "29496265"
    },
    {
      "entity1": "OXB",
      "entity2": "OX2R",
      "relationship": "binds_to",
      "evidence_text": "Both OXA and OXB peptides bind to two G-coupled receptors, orexin-1 (OX1R) and orexin-2 (OX2R) receptor, though with different binding affinity.",
      "confidence": 0.96,
      "pmid": "29496265"
    },
    {
      "entity1": "OXB",
      "entity2": "OX2R",
      "relationship": "cooccurs_with",
      "evidence_text": "Immunohistochemical staining of sections from caput, corpus and cauda segments of the organ showed intense signals for both OXB and OX2R in the principal cells of the lining epithelium.",
      "confidence": 0.92,
      "pmid": "29496265"
    },
    {
      "entity1": "Orexin",
      "entity2": "fear expression",
      "relationship": "inhibits",
      "evidence_text": "dual orexin receptor antagonists (DORAs) inhibit fear acquisition and expression.",
      "confidence": 0.94,
      "pmid": "35618150"
    },
    {
      "entity1": "Orexin",
      "entity2": "fear extinction",
      "relationship": "inhibits",
      "evidence_text": "Orexin activation of an infralimbic-amygdala circuit impedes fear extinction.",
      "confidence": 0.9,
      "pmid": "35618150"
    },
    {
      "entity1": "Orexin",
      "entity2": "startle responses",
      "relationship": "inhibits",
      "evidence_text": "Blockade of orexin receptors reduces fear\u2011conditioned startle responses.",
      "confidence": 0.93,
      "pmid": "35618150"
    },
    {
      "entity1": "Orexin",
      "entity2": "wakefulness",
      "relationship": "activates",
      "evidence_text": "Increased orexin activity impairs sleep by promoting wakefulness and reducing total sleep time.",
      "confidence": 0.92,
      "pmid": "35618150"
    },
    {
      "entity1": "OX1R",
      "entity2": "depressive behaviors",
      "relationship": "inhibits",
      "evidence_text": "Chronic orexin-1 receptor blockage attenuates depressive behaviors.",
      "confidence": 0.94,
      "pmid": "36154849"
    },
    {
      "entity1": "OX1R",
      "entity2": "PSD-95 expression",
      "relationship": "activates",
      "evidence_text": "Chronic orexin-1 receptor blockage ... provokes PSD-95 expression in a rat model of depression.",
      "confidence": 0.9,
      "pmid": "36154849"
    },
    {
      "entity1": "OXRs",
      "entity2": "anxiety",
      "relationship": "inhibits",
      "evidence_text": "blocking of both OXRs ... impeded acute stress\u2011induced increased anxiety.",
      "confidence": 0.88,
      "pmid": "30458283"
    },
    {
      "entity1": "OX2R antagonists",
      "entity2": "wakefulness",
      "relationship": "inhibits",
      "evidence_text": "Dual and selective orexin-2 receptor antagonists have shown efficacy in inducing sleep ... by accelerating sleep onset and improving sleep efficiency and total sleep time.",
      "confidence": 0.91,
      "pmid": "34052807"
    },
    {
      "entity1": "danavorexton",
      "entity2": "sleep latency",
      "relationship": "inhibits",
      "evidence_text": "danavorexton ... was associated with marked improvements in sleep latency in both NT1 and NT2.",
      "confidence": 0.95,
      "pmid": "35994639"
    },
    {
      "entity1": "OX2R agonist",
      "entity2": "cataplexy-like episodes",
      "relationship": "inhibits",
      "evidence_text": "danavorexton reduced sleep/wakefulness fragmentation and cataplexy\u2011like episodes during the active phase.",
      "confidence": 0.93,
      "pmid": "35994639"
    },
    {
      "entity1": "OX2R",
      "entity2": "neuronal activity",
      "relationship": "activates",
      "evidence_text": "blockade of OX2Rs ... prevented the excitatory/inhibitory changes induced by tramadol, indicating OX2R activity contributes to neuronal response.",
      "confidence": 0.89,
      "pmid": "35313383"
    },
    {
      "entity1": "OXB",
      "entity2": "spermatogenesis",
      "relationship": "regulates",
      "evidence_text": "The results suggest the expression of OXB and OX2R in mouse testis and their possible regulatory role in spermatogenesis and steroidogenesis.",
      "confidence": 0.9,
      "pmid": "36841281"
    },
    {
      "entity1": "OX2R",
      "entity2": "steroidogenesis",
      "relationship": "regulates",
      "evidence_text": "The results suggest the expression of OXB and OX2R in mouse testis and their possible regulatory role in spermatogenesis and steroidogenesis.",
      "confidence": 0.9,
      "pmid": "36841281"
    },
    {
      "entity1": "Orexin",
      "entity2": "sleep",
      "relationship": "regulates",
      "evidence_text": "Recent evidence suggests the central orexin system, particularly orexins A and B and their receptors, have a key regulatory role for sleep in animal and human models.",
      "confidence": 0.92,
      "pmid": "36148653"
    },
    {
      "entity1": "Orexin",
      "entity2": "sympathetic activity",
      "relationship": "regulates",
      "evidence_text": "orexin system ... have a key regulatory role for ... sympathetic regulation.",
      "confidence": 0.91,
      "pmid": "36148653"
    },
    {
      "entity1": "OX1R",
      "entity2": "apoptosis",
      "relationship": "activates",
      "evidence_text": "identification of OX1R expression in digestive cancers ... its ability to trigger mitochondrial apoptosis in tumoral cells.",
      "confidence": 0.88,
      "pmid": "35966051"
    },
    {
      "entity1": "Orexin",
      "entity2": "blood pressure",
      "relationship": "activates",
      "evidence_text": "orexinergic stimulation results in increased blood pressure and heart rate.",
      "confidence": 0.94,
      "pmid": "29992504"
    },
    {
      "entity1": "Orexin antagonism",
      "entity2": "blood pressure",
      "relationship": "inhibits",
      "evidence_text": "this effect may be efficiently attenuated by orexinergic antagonism.",
      "confidence": 0.9,
      "pmid": "29992504"
    },
    {
      "entity1": "TCS OX2 29",
      "entity2": "detrusor overactivity",
      "relationship": "inhibits",
      "evidence_text": "TCS ... normalizes the cystometric parameters corresponding to overactivity of the detrusor.",
      "confidence": 0.93,
      "pmid": "39402852"
    },
    {
      "entity1": "TCS OX2 29",
      "entity2": "depressive response",
      "relationship": "inhibits",
      "evidence_text": "TCS ... reverses the pro\u2011depressive response.",
      "confidence": 0.93,
      "pmid": "39402852"
    },
    {
      "entity1": "OX1R",
      "entity2": "orexin A",
      "relationship": "binds_to",
      "evidence_text": "OX1R has selective affinity for orexin A.",
      "confidence": 0.95,
      "pmid": "37189339"
    },
    {
      "entity1": "orexin",
      "entity2": "monoaminergic neurons",
      "relationship": "activates",
      "evidence_text": "Orexin neurons are thought to act primarily on monoaminergic neurons to maintain arousal and vigilance.",
      "confidence": 0.8,
      "pmid": "34052806"
    },
    {
      "entity1": "orexin",
      "entity2": "dopaminergic system",
      "relationship": "associated_with",
      "evidence_text": "Orexin also has close interactions with the dopaminergic system.",
      "confidence": 0.78,
      "pmid": "34052806"
    },
    {
      "entity1": "hypocretin deficiency",
      "entity2": "Narcolepsy type 1",
      "relationship": "associated_with",
      "evidence_text": "Narcolepsy type 1 (NT1) ... symptoms are due to hypocretin deficiency.",
      "confidence": 0.9,
      "pmid": "39241492"
    },
    {
      "entity1": "estradiol",
      "entity2": "orexin system",
      "relationship": "regulates",
      "evidence_text": "fluctuations in circulating estradiol (E2) ... alter orexin ... peptide production and receptor activity.",
      "confidence": 0.85,
      "pmid": "36571628"
    },
    {
      "entity1": "SB-334867",
      "entity2": "OX1R",
      "relationship": "inhibits",
      "evidence_text": "The combination of orexin-1 receptor antagonist SB-334867 and orexin-B with morphine significantly increased the analgesic effect.",
      "confidence": 0.9,
      "pmid": "36480169"
    },
    {
      "entity1": "orexin-B",
      "entity2": "OX2R",
      "relationship": "activates",
      "evidence_text": "The combination of orexin-1 receptor antagonist SB-334867 and orexin-B with morphine ...",
      "confidence": 0.9,
      "pmid": "36480169"
    },
    {
      "entity1": "orexin-A",
      "entity2": "dopamine D2 receptor",
      "relationship": "activates",
      "evidence_text": "Orexin-A up-regulates dopamine D2 receptor and mRNA in the nucleus accumbens Shell.",
      "confidence": 0.95,
      "pmid": "33170427"
    },
    {
      "entity1": "OX2R",
      "entity2": "ERK1/2",
      "relationship": "activates",
      "evidence_text": "These mutants exhibited decreased phosphorylation levels of ERK1/2 ... compared with wild-type pOX2R.",
      "confidence": 0.85,
      "pmid": "32296386"
    },
    {
      "entity1": "OX2R",
      "entity2": "p38",
      "relationship": "activates",
      "evidence_text": "These mutants exhibited decreased phosphorylation levels of ... p38 ... compared with wild-type pOX2R.",
      "confidence": 0.85,
      "pmid": "32296386"
    },
    {
      "entity1": "OX2R",
      "entity2": "CREB",
      "relationship": "activates",
      "evidence_text": "These mutants exhibited decreased phosphorylation levels of ... CREB to some degree compared with wild-type pOX2R.",
      "confidence": 0.85,
      "pmid": "32296386"
    },
    {
      "entity1": "OX2R",
      "entity2": "amyloid \u03b2 (A\u03b2)",
      "relationship": "inhibits",
      "evidence_text": "OX2R blockade ... reduced A\u03b2 pathology ... in 3xTg-AD mice.",
      "confidence": 0.9,
      "pmid": "38682858"
    },
    {
      "entity1": "OX2R",
      "entity2": "tau phosphorylation",
      "relationship": "inhibits",
      "evidence_text": "OX2R blockade ... reduced ... tau phosphorylation ... in 3xTg-AD mice.",
      "confidence": 0.9,
      "pmid": "38682858"
    },
    {
      "entity1": "OX2R",
      "entity2": "neuroinflammation",
      "relationship": "inhibits",
      "evidence_text": "OX2R blockade ... alleviated ... neuroinflammation in 3xTg-AD mice.",
      "confidence": 0.9,
      "pmid": "38682858"
    },
    {
      "entity1": "lemborexant",
      "entity2": "OX1R",
      "relationship": "inhibits",
      "evidence_text": "Lemborexant is a dual antagonist acting on both two orexin receptors, the orexin 1 (OX1R) and 2 receptor (OX2R), with stronger inhibitory effects on OX2R.",
      "confidence": 0.9,
      "pmid": "33642529"
    },
    {
      "entity1": "lemborexant",
      "entity2": "OX2R",
      "relationship": "inhibits",
      "evidence_text": "Lemborexant is a dual antagonist ... with stronger inhibitory effects on OX2R.",
      "confidence": 0.9,
      "pmid": "33642529"
    },
    {
      "entity1": "hyper-activation of orexin system",
      "entity2": "insomnia",
      "relationship": "associated_with",
      "evidence_text": "Hyper-activation of the orexin system also causes sleep disturbances, such as insomnia, and hence, suvorexant ... has been clinically used to treat insomnia.",
      "confidence": 0.85,
      "pmid": "29289556"
    },
    {
      "entity1": "suvorexant",
      "entity2": "orexin receptors",
      "relationship": "inhibits",
      "evidence_text": "suvorexant, an orexin receptor antagonist, has been clinically used to treat insomnia.",
      "confidence": 0.88,
      "pmid": "29289556"
    },
    {
      "entity1": "CVN766",
      "entity2": "OX1R",
      "relationship": "inhibits",
      "evidence_text": "CVN766, a potent orexin 1 receptor antagonist that has greater than 1000-fold selectivity for the orexin 1 receptor over the orexin 2 receptor.",
      "confidence": 0.95,
      "pmid": "38295907"
    },
    {
      "entity1": "orexin B",
      "entity2": "OX2R",
      "relationship": "activates",
      "evidence_text": "Supradural orexin B induced migraine-like pain behaviors ... increased TNC ERK phosphorylation exclusively in males.",
      "confidence": 0.92,
      "pmid": "39233656"
    },
    {
      "entity1": "OX2R",
      "entity2": "ERK phosphorylation",
      "relationship": "activates",
      "evidence_text": "Supradural orexin B induced ... increased TNC ERK phosphorylation ... OX2R expression was higher in male TG.",
      "confidence": 0.9,
      "pmid": "39233656"
    },
    {
      "entity1": "suvorexant",
      "entity2": "orexin signaling",
      "relationship": "inhibits",
      "evidence_text": "Blockade of orexin signaling with supradural suvorexant, a dual orexin receptor antagonist, prevented ... migraine-like pain in males.",
      "confidence": 0.88,
      "pmid": "39233656"
    },
    {
      "entity1": "OxR1",
      "entity2": "odor-attractive behavior",
      "relationship": "activates",
      "evidence_text": "When odor-food reward associated mice underwent OxR1 antagonist injection in the amOT, their odor-attractive behavior was suppressed.",
      "confidence": 0.85,
      "pmid": "39725686"
    },
    {
      "entity1": "OxR1",
      "entity2": "odor-aversive behavior",
      "relationship": "inhibits",
      "evidence_text": "OxR1 antagonist injection ... odor-aversive behavior was conversely induced.",
      "confidence": 0.85,
      "pmid": "39725686"
    },
    {
      "entity1": "hypocretin/orexin",
      "entity2": "cocaine abuse",
      "relationship": "activates",
      "evidence_text": "blocking hcrt/ox transmission using systemic or site-directed pharmacological antagonists markedly reduced motivated drug-taking as well as drug-seeking",
      "confidence": 0.9,
      "pmid": "30796894"
    },
    {
      "entity1": "OX2R",
      "entity2": "5-HT1AR",
      "relationship": "binds_to",
      "evidence_text": "we firstly demonstrated the heterodimer formation of 5-HT1AR and OX2R",
      "confidence": 0.95,
      "pmid": "30481562"
    },
    {
      "entity1": "OX2R",
      "entity2": "ERK",
      "relationship": "inhibits",
      "evidence_text": "western blotting data showed that 5-HT1AR and OX2R heterodimer decreased the levels of phosphorylation of extracellular signal-regulated kinase (ERK)",
      "confidence": 0.9,
      "pmid": "30481562"
    },
    {
      "entity1": "OX2R",
      "entity2": "CREB",
      "relationship": "inhibits",
      "evidence_text": "western blotting data showed that 5-HT1AR and OX2R heterodimer decreased the levels of phosphorylation of ... cAMP-response element-binding protein (CREB)",
      "confidence": 0.9,
      "pmid": "30481562"
    },
    {
      "entity1": "Danavorexton",
      "entity2": "OX2R",
      "relationship": "activates",
      "evidence_text": "Danavorexton (TAK-925) is an agonist for orexin receptor 2 where it promotes recovery from inhalational and i.v. anaesthesia and opioid sedation",
      "confidence": 0.95,
      "pmid": "38346840"
    },
    {
      "entity1": "TS-142",
      "entity2": "OX1R",
      "relationship": "inhibits",
      "evidence_text": "Novel compound with potent antagonistic activity against orexin receptors may be new treatment option for patients with insomnia",
      "confidence": 0.9,
      "pmid": "35296912"
    },
    {
      "entity1": "TS-142",
      "entity2": "OX2R",
      "relationship": "inhibits",
      "evidence_text": "Novel compound with potent antagonistic activity against orexin receptors may be new treatment option for patients with insomnia",
      "confidence": 0.9,
      "pmid": "35296912"
    },
    {
      "entity1": "orexin-A",
      "entity2": "analgesia",
      "relationship": "activates",
      "evidence_text": "orexin peptides induce analgesia that is comparable to morphine",
      "confidence": 0.9,
      "pmid": "28552056"
    },
    {
      "entity1": "orexin-B",
      "entity2": "subthalamic nucleus neurons",
      "relationship": "activates",
      "evidence_text": "The subthalamic neurons are activated by both orexin-A and orexin-B",
      "confidence": 0.95,
      "pmid": "29138106"
    },
    {
      "entity1": "orexin-A",
      "entity2": "subthalamic nucleus neurons",
      "relationship": "activates",
      "evidence_text": "The subthalamic neurons are activated by both orexin-A and orexin-B",
      "confidence": 0.95,
      "pmid": "29138106"
    },
    {
      "entity1": "SDM-878",
      "entity2": "OX2R",
      "relationship": "inhibits",
      "evidence_text": "SDM-878 showed potent inhibitory activities for human and rat OX",
      "confidence": 0.95,
      "pmid": "32337858"
    },
    {
      "entity1": "OX2R",
      "entity2": "resilience",
      "relationship": "activates",
      "evidence_text": "Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression",
      "confidence": 0.9,
      "pmid": "30240784"
    },
    {
      "entity1": "OX2R",
      "entity2": "susceptibility to stress, anxiety and depression",
      "relationship": "inhibits",
      "evidence_text": "Orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression",
      "confidence": 0.9,
      "pmid": "30240784"
    },
    {
      "entity1": "OX2R",
      "entity2": "myocardial protection",
      "relationship": "activates",
      "evidence_text": "Role of Orexin-B/Orexin 2 receptor in myocardial protection",
      "confidence": 0.9,
      "pmid": "30948623"
    },
    {
      "entity1": "TAK-925",
      "entity2": "HCRTR2",
      "relationship": "activates",
      "evidence_text": "TAK-925 (1-10 mg/kg, s.c.) and ARN-776 (1-10 mg/kg, i.p.) were injected ...",
      "confidence": 0.95,
      "pmid": "36808670"
    },
    {
      "entity1": "ARN-776",
      "entity2": "HCRTR2",
      "relationship": "activates",
      "evidence_text": "TAK-925 (1-10 mg/kg, s.c.) and ARN-776 (1-10 mg/kg, i.p.) were injected ...",
      "confidence": 0.95,
      "pmid": "36808670"
    },
    {
      "entity1": "OX2R",
      "entity2": "Na+/Ca2+ exchanger",
      "relationship": "activates",
      "evidence_text": "the main acute downstream responses of OXR activation are ... the activation of the Na+/Ca2+ exchanger",
      "confidence": 0.9,
      "pmid": "34052812"
    },
    {
      "entity1": "OX2R",
      "entity2": "2-arachidonoyl glycerol",
      "relationship": "activates",
      "evidence_text": "may also ... lead to the production of the potent endocannabinoid (eCB), 2-arachidonoyl glycerol",
      "confidence": 0.9,
      "pmid": "34052812"
    },
    {
      "entity1": "ZGW",
      "entity2": "orexin-A",
      "relationship": "activates",
      "evidence_text": "it was upregulated for the orexin-A ... expression from the hypothalamus and tibiae",
      "confidence": 0.9,
      "pmid": "34939389"
    },
    {
      "entity1": "ZGW",
      "entity2": "OX2R",
      "relationship": "activates",
      "evidence_text": "it was upregulated for the ... OX2R mRNA or protein expression",
      "confidence": 0.9,
      "pmid": "34939389"
    },
    {
      "entity1": "ZGW",
      "entity2": "OX1R",
      "relationship": "inhibits",
      "evidence_text": "while downregulated for the OX1R mRNA and protein expression",
      "confidence": 0.9,
      "pmid": "34939389"
    },
    {
      "entity1": "(S)-1-amino-tetralin derivative",
      "entity2": "OX2R",
      "relationship": "activates",
      "evidence_text": "(-)-6 having a (S)-1-amino-tetralin skeleton showed a OX",
      "confidence": 0.9,
      "pmid": "35051577"
    },
    {
      "entity1": "OX1R antagonist",
      "entity2": "drug addiction",
      "relationship": "inhibits",
      "evidence_text": "Blockade of the orexin-1 receptor has been suggested as a potential strategy for the treatment of drug addiction",
      "confidence": 0.85,
      "pmid": "29129052"
    },
    {
      "entity1": "HCRTR2",
      "entity2": "hyperarousal",
      "relationship": "inhibits",
      "evidence_text": "loss of Hcrtr2 ... induced a dramatic increase in theta ... hyperarousal",
      "confidence": 0.9,
      "pmid": "38123729"
    },
    {
      "entity1": "sleep improvement",
      "entity2": "seizures",
      "relationship": "inhibits",
      "evidence_text": "Accordingly, sleep improvement can be a therapeutic strategy for reducing seizures and better managing epilepsy.",
      "confidence": 0.9,
      "pmid": "37212716"
    },
    {
      "entity1": "DORAs",
      "entity2": "sleep impairment",
      "relationship": "regulates",
      "evidence_text": "the recently approved dual orexin receptor antagonists (DORAs) have been suggested for treating sleep impairment and insomnia in PWE.",
      "confidence": 0.9,
      "pmid": "37212716"
    },
    {
      "entity1": "DORAs",
      "entity2": "epilepsy",
      "relationship": "inhibits",
      "evidence_text": "the antagonism to the orexin system by DORAs can improve epilepsy by both a direct and a sleep-mediated (indirect) effect.",
      "confidence": 0.9,
      "pmid": "37212716"
    },
    {
      "entity1": "orexin-B",
      "entity2": "contractile shortening",
      "relationship": "activates",
      "evidence_text": "In isolated rat cardiomyocytes, only orexin-B (OR-B) caused an increase in contractile shortening, independent of diastolic or systolic calcium levels.",
      "confidence": 0.9,
      "pmid": "30467191"
    },
    {
      "entity1": "MK-1064",
      "entity2": "SWS onset",
      "relationship": "activates",
      "evidence_text": "Acute MK-1064 hastened SWS onset and increased the number of SWS episodes, without increasing sleep fragmentation in AIE and controls.",
      "confidence": 0.9,
      "pmid": "32424852"
    },
    {
      "entity1": "MK-1064",
      "entity2": "SWS episodes",
      "relationship": "activates",
      "evidence_text": "Acute MK-1064 hastened SWS onset and increased the number of SWS episodes, without increasing sleep fragmentation in AIE and controls.",
      "confidence": 0.9,
      "pmid": "32424852"
    },
    {
      "entity1": "AIE",
      "entity2": "fragmentation of slow wave sleep",
      "relationship": "associated_with",
      "evidence_text": "Female AIE rats exhibited lasting changes in sleep compared to controls. This was demonstrated by increased fragmentation of slow wave sleep (SWS) and rapid eye movement sleep.",
      "confidence": 0.9,
      "pmid": "32424852"
    }
  ],
  "valid_relationships": [
    {
      "entity1": "Almorexant",
      "entity2": "orexin system",
      "relationship": "inhibits",
      "evidence_text": "Almorexant is now mainly used as a commercial specific inhibitor of the orexin system in animal studies due to safety issues.",
      "confidence": 0.9,
      "pmid": "35972717"
    },
    {
      "entity1": "Orexin-A",
      "entity2": "HCRTR1",
      "relationship": "binds_to",
      "evidence_text": "the hypocretins/orexins are two excitatory neuropeptides... that are the endogenous ligands for two G-protein-coupled receptors, HCRTR1/OX1R and HCRTR2/OX2R.",
      "confidence": 1.0,
      "pmid": "34052813"
    },
    {
      "entity1": "Orexin-A",
      "entity2": "HCRTR2",
      "relationship": "binds_to",
      "evidence_text": "the hypocretins/orexins are two excitatory neuropeptides... that are the endogenous ligands for two G-protein-coupled receptors, HCRTR1/OX1R and HCRTR2/OX2R.",
      "confidence": 1.0,
      "pmid": "34052813"
    },
    {
      "entity1": "orexin system",
      "entity2": "Alzheimer's disease",
      "relationship": "associated_with",
      "evidence_text": "Dysregulation of the orexin system occurs in aging and AD, positioning ORAs as advantageous for these populations.",
      "confidence": 0.8,
      "pmid": "37708433"
    },
    {
      "entity1": "orexin system",
      "entity2": "Alzheimer's disease",
      "relationship": "associated_with",
      "evidence_text": "Given the high prevalence of sleep disturbances in Alzheimer's disease (AD) and their reported involvement in AD pathophysiology, the orexin system is hypothesized to contribute to the disease pathogenesis.",
      "confidence": 0.85,
      "pmid": "39365407"
    },
    {
      "entity1": "Orexin-A",
      "entity2": "HCRTR1",
      "relationship": "inhibits",
      "evidence_text": "Overall, it was concluded that OXA exerts neuroprotective effect ... by Inhibiting OX1R-mediated NF-\u03baB, MAPK/ERK and MAPK/p38 signaling pathways.",
      "confidence": 0.95,
      "pmid": "34358627"
    },
    {
      "entity1": "Orexin-A",
      "entity2": "NF-\u03baB",
      "relationship": "inhibits",
      "evidence_text": "Overall, it was concluded that OXA exerts neuroprotective effect ... by Inhibiting OX1R-mediated NF-\u03baB, MAPK/ERK and MAPK/p38 signaling pathways.",
      "confidence": 0.9,
      "pmid": "34358627"
    },
    {
      "entity1": "TAK-994",
      "entity2": "OX2R",
      "relationship": "activates",
      "evidence_text": "TAK-994, an oral orexin receptor 2-selective agonist, in patients with narcolepsy type 1.",
      "confidence": 0.95,
      "pmid": "37494485"
    },
    {
      "entity1": "MSZRD",
      "entity2": "Orexin-A",
      "relationship": "inhibits",
      "evidence_text": "MSZRD significantly downregulated the serum Orexin-A content in insomnia mice.",
      "confidence": 0.9,
      "pmid": "34509822"
    },
    {
      "entity1": "almorexant",
      "entity2": "orexin receptors",
      "relationship": "inhibits",
      "evidence_text": "injected intraperitoneally with almorexant, a dual orexin receptor antagonist (DORA)",
      "confidence": 0.95,
      "pmid": "39047304"
    },
    {
      "entity1": "almorexant",
      "entity2": "A\u03b2 deposition",
      "relationship": "inhibits",
      "evidence_text": "The application of almorexant can increase the total sleep time of sleep-deprived mice and reduce cognitive impairment and A\u03b2 deposition",
      "confidence": 0.92,
      "pmid": "39047304"
    },
    {
      "entity1": "almorexant",
      "entity2": "Aquaporin-4 polarity",
      "relationship": "associated_with",
      "evidence_text": "which is related to the improvement in Aquaporin-4 polarity",
      "confidence": 0.85,
      "pmid": "39047304"
    },
    {
      "entity1": "sleep deprivation",
      "entity2": "A\u03b2 deposition",
      "relationship": "activates",
      "evidence_text": "sleep deprivation aggravated learning and memory impairment and increased brain \u03b2-amyloid (A\u03b2) deposition in mice with AD",
      "confidence": 0.9,
      "pmid": "39047304"
    },
    {
      "entity1": "orexin",
      "entity2": "OX1R",
      "relationship": "activates",
      "evidence_text": "Orexins ... bind and activating two G-protein-coupled receptors (GPCRs), orexin receptor type 1 (OX1R) and type 2 (OX2R)",
      "confidence": 0.96,
      "pmid": "30002617"
    },
    {
      "entity1": "orexin",
      "entity2": "OX2R",
      "relationship": "activates",
      "evidence_text": "Orexins ... bind and activating two G-protein-coupled receptors (GPCRs), orexin receptor type 1 (OX1R) and type 2 (OX2R)",
      "confidence": 0.96,
      "pmid": "30002617"
    },
    {
      "entity1": "orexin",
      "entity2": "OX1R",
      "relationship": "activates",
      "evidence_text": "Orexin enhances learning and memory as well as reward, stress, seizures, and epilepsy, partly through OX1Rs",
      "confidence": 0.88,
      "pmid": "35180935"
    },
    {
      "entity1": "5-HT1AR",
      "entity2": "OX1R",
      "relationship": "binds_to",
      "evidence_text": "5-HT1AR and OX1R form constitutive heterodimers",
      "confidence": 0.94,
      "pmid": "35338110"
    },
    {
      "entity1": "orexin system",
      "entity2": "hypertension",
      "relationship": "activates",
      "evidence_text": "hyperactivity of the orexin system contributes to hypertension",
      "confidence": 0.9,
      "pmid": "28349223"
    },
    {
      "entity1": "20d",
      "entity2": "OX2R",
      "relationship": "activates",
      "evidence_text": "20d and 28d showed full agonist activity against OX",
      "confidence": 0.89,
      "pmid": "36690040"
    },
    {
      "entity1": "28d",
      "entity2": "OX2R",
      "relationship": "activates",
      "evidence_text": "20d and 28d showed full agonist activity against OX",
      "confidence": 0.89,
      "pmid": "36690040"
    },
    {
      "entity1": "OX2R antagonist",
      "entity2": "OX2R",
      "relationship": "inhibits",
      "evidence_text": "dual orexin receptor antagonist suvorexant",
      "confidence": 0.9,
      "pmid": "37553894"
    },
    {
      "entity1": "OXA",
      "entity2": "OX1R",
      "relationship": "binds_to",
      "evidence_text": "Both OXA and OXB peptides bind to two G-coupled receptors, orexin-1 (OX1R) and orexin-2 (OX2R) receptor, though with different binding affinity.",
      "confidence": 0.96,
      "pmid": "29496265"
    },
    {
      "entity1": "OXA",
      "entity2": "OX2R",
      "relationship": "binds_to",
      "evidence_text": "Both OXA and OXB peptides bind to two G-coupled receptors, orexin-1 (OX1R) and orexin-2 (OX2R) receptor, though with different binding affinity.",
      "confidence": 0.96,
      "pmid": "29496265"
    },
    {
      "entity1": "OXB",
      "entity2": "OX1R",
      "relationship": "binds_to",
      "evidence_text": "Both OXA and OXB peptides bind to two G-coupled receptors, orexin-1 (OX1R) and orexin-2 (OX2R) receptor, though with different binding affinity.",
      "confidence": 0.96,
      "pmid": "29496265"
    },
    {
      "entity1": "OXB",
      "entity2": "OX2R",
      "relationship": "binds_to",
      "evidence_text": "Both OXA and OXB peptides bind to two G-coupled receptors, orexin-1 (OX1R) and orexin-2 (OX2R) receptor, though with different binding affinity.",
      "confidence": 0.96,
      "pmid": "29496265"
    },
    {
      "entity1": "OXB",
      "entity2": "OX2R",
      "relationship": "cooccurs_with",
      "evidence_text": "Immunohistochemical staining of sections from caput, corpus and cauda segments of the organ showed intense signals for both OXB and OX2R in the principal cells of the lining epithelium.",
      "confidence": 0.92,
      "pmid": "29496265"
    },
    {
      "entity1": "Orexin",
      "entity2": "fear expression",
      "relationship": "inhibits",
      "evidence_text": "dual orexin receptor antagonists (DORAs) inhibit fear acquisition and expression.",
      "confidence": 0.94,
      "pmid": "35618150"
    },
    {
      "entity1": "Orexin",
      "entity2": "fear extinction",
      "relationship": "inhibits",
      "evidence_text": "Orexin activation of an infralimbic-amygdala circuit impedes fear extinction.",
      "confidence": 0.9,
      "pmid": "35618150"
    },
    {
      "entity1": "Orexin",
      "entity2": "startle responses",
      "relationship": "inhibits",
      "evidence_text": "Blockade of orexin receptors reduces fear\u2011conditioned startle responses.",
      "confidence": 0.93,
      "pmid": "35618150"
    },
    {
      "entity1": "Orexin",
      "entity2": "wakefulness",
      "relationship": "activates",
      "evidence_text": "Increased orexin activity impairs sleep by promoting wakefulness and reducing total sleep time.",
      "confidence": 0.92,
      "pmid": "35618150"
    },
    {
      "entity1": "OX2R antagonists",
      "entity2": "wakefulness",
      "relationship": "inhibits",
      "evidence_text": "Dual and selective orexin-2 receptor antagonists have shown efficacy in inducing sleep ... by accelerating sleep onset and improving sleep efficiency and total sleep time.",
      "confidence": 0.91,
      "pmid": "34052807"
    },
    {
      "entity1": "danavorexton",
      "entity2": "sleep latency",
      "relationship": "inhibits",
      "evidence_text": "danavorexton ... was associated with marked improvements in sleep latency in both NT1 and NT2.",
      "confidence": 0.95,
      "pmid": "35994639"
    },
    {
      "entity1": "OX2R agonist",
      "entity2": "cataplexy-like episodes",
      "relationship": "inhibits",
      "evidence_text": "danavorexton reduced sleep/wakefulness fragmentation and cataplexy\u2011like episodes during the active phase.",
      "confidence": 0.93,
      "pmid": "35994639"
    },
    {
      "entity1": "OXB",
      "entity2": "spermatogenesis",
      "relationship": "regulates",
      "evidence_text": "The results suggest the expression of OXB and OX2R in mouse testis and their possible regulatory role in spermatogenesis and steroidogenesis.",
      "confidence": 0.9,
      "pmid": "36841281"
    },
    {
      "entity1": "OX2R",
      "entity2": "steroidogenesis",
      "relationship": "regulates",
      "evidence_text": "The results suggest the expression of OXB and OX2R in mouse testis and their possible regulatory role in spermatogenesis and steroidogenesis.",
      "confidence": 0.9,
      "pmid": "36841281"
    },
    {
      "entity1": "Orexin",
      "entity2": "sleep",
      "relationship": "regulates",
      "evidence_text": "Recent evidence suggests the central orexin system, particularly orexins A and B and their receptors, have a key regulatory role for sleep in animal and human models.",
      "confidence": 0.92,
      "pmid": "36148653"
    },
    {
      "entity1": "Orexin antagonism",
      "entity2": "blood pressure",
      "relationship": "inhibits",
      "evidence_text": "this effect may be efficiently attenuated by orexinergic antagonism.",
      "confidence": 0.9,
      "pmid": "29992504"
    },
    {
      "entity1": "orexin",
      "entity2": "monoaminergic neurons",
      "relationship": "activates",
      "evidence_text": "Orexin neurons are thought to act primarily on monoaminergic neurons to maintain arousal and vigilance.",
      "confidence": 0.8,
      "pmid": "34052806"
    },
    {
      "entity1": "hypocretin deficiency",
      "entity2": "Narcolepsy type 1",
      "relationship": "associated_with",
      "evidence_text": "Narcolepsy type 1 (NT1) ... symptoms are due to hypocretin deficiency.",
      "confidence": 0.9,
      "pmid": "39241492"
    },
    {
      "entity1": "SB-334867",
      "entity2": "OX1R",
      "relationship": "inhibits",
      "evidence_text": "The combination of orexin-1 receptor antagonist SB-334867 and orexin-B with morphine significantly increased the analgesic effect.",
      "confidence": 0.9,
      "pmid": "36480169"
    },
    {
      "entity1": "OX2R",
      "entity2": "ERK1/2",
      "relationship": "activates",
      "evidence_text": "These mutants exhibited decreased phosphorylation levels of ERK1/2 ... compared with wild-type pOX2R.",
      "confidence": 0.85,
      "pmid": "32296386"
    },
    {
      "entity1": "OX2R",
      "entity2": "p38",
      "relationship": "activates",
      "evidence_text": "These mutants exhibited decreased phosphorylation levels of ... p38 ... compared with wild-type pOX2R.",
      "confidence": 0.85,
      "pmid": "32296386"
    },
    {
      "entity1": "OX2R",
      "entity2": "CREB",
      "relationship": "activates",
      "evidence_text": "These mutants exhibited decreased phosphorylation levels of ... CREB to some degree compared with wild-type pOX2R.",
      "confidence": 0.85,
      "pmid": "32296386"
    },
    {
      "entity1": "lemborexant",
      "entity2": "OX1R",
      "relationship": "inhibits",
      "evidence_text": "Lemborexant is a dual antagonist acting on both two orexin receptors, the orexin 1 (OX1R) and 2 receptor (OX2R), with stronger inhibitory effects on OX2R.",
      "confidence": 0.9,
      "pmid": "33642529"
    },
    {
      "entity1": "hyper-activation of orexin system",
      "entity2": "insomnia",
      "relationship": "associated_with",
      "evidence_text": "Hyper-activation of the orexin system also causes sleep disturbances, such as insomnia, and hence, suvorexant ... has been clinically used to treat insomnia.",
      "confidence": 0.85,
      "pmid": "29289556"
    },
    {
      "entity1": "suvorexant",
      "entity2": "orexin receptors",
      "relationship": "inhibits",
      "evidence_text": "suvorexant, an orexin receptor antagonist, has been clinically used to treat insomnia.",
      "confidence": 0.88,
      "pmid": "29289556"
    },
    {
      "entity1": "CVN766",
      "entity2": "OX1R",
      "relationship": "inhibits",
      "evidence_text": "CVN766, a potent orexin 1 receptor antagonist that has greater than 1000-fold selectivity for the orexin 1 receptor over the orexin 2 receptor.",
      "confidence": 0.95,
      "pmid": "38295907"
    },
    {
      "entity1": "orexin B",
      "entity2": "OX2R",
      "relationship": "activates",
      "evidence_text": "Supradural orexin B induced migraine-like pain behaviors ... increased TNC ERK phosphorylation exclusively in males.",
      "confidence": 0.92,
      "pmid": "39233656"
    },
    {
      "entity1": "suvorexant",
      "entity2": "orexin signaling",
      "relationship": "inhibits",
      "evidence_text": "Blockade of orexin signaling with supradural suvorexant, a dual orexin receptor antagonist, prevented ... migraine-like pain in males.",
      "confidence": 0.88,
      "pmid": "39233656"
    },
    {
      "entity1": "OxR1",
      "entity2": "odor-attractive behavior",
      "relationship": "activates",
      "evidence_text": "When odor-food reward associated mice underwent OxR1 antagonist injection in the amOT, their odor-attractive behavior was suppressed.",
      "confidence": 0.85,
      "pmid": "39725686"
    },
    {
      "entity1": "hypocretin/orexin",
      "entity2": "cocaine abuse",
      "relationship": "activates",
      "evidence_text": "blocking hcrt/ox transmission using systemic or site-directed pharmacological antagonists markedly reduced motivated drug-taking as well as drug-seeking",
      "confidence": 0.9,
      "pmid": "30796894"
    },
    {
      "entity1": "OX2R",
      "entity2": "5-HT1AR",
      "relationship": "binds_to",
      "evidence_text": "we firstly demonstrated the heterodimer formation of 5-HT1AR and OX2R",
      "confidence": 0.95,
      "pmid": "30481562"
    },
    {
      "entity1": "OX2R",
      "entity2": "ERK",
      "relationship": "inhibits",
      "evidence_text": "western blotting data showed that 5-HT1AR and OX2R heterodimer decreased the levels of phosphorylation of extracellular signal-regulated kinase (ERK)",
      "confidence": 0.9,
      "pmid": "30481562"
    },
    {
      "entity1": "OX2R",
      "entity2": "CREB",
      "relationship": "inhibits",
      "evidence_text": "western blotting data showed that 5-HT1AR and OX2R heterodimer decreased the levels of phosphorylation of ... cAMP-response element-binding protein (CREB)",
      "confidence": 0.9,
      "pmid": "30481562"
    },
    {
      "entity1": "Danavorexton",
      "entity2": "OX2R",
      "relationship": "activates",
      "evidence_text": "Danavorexton (TAK-925) is an agonist for orexin receptor 2 where it promotes recovery from inhalational and i.v. anaesthesia and opioid sedation",
      "confidence": 0.95,
      "pmid": "38346840"
    },
    {
      "entity1": "TS-142",
      "entity2": "OX1R",
      "relationship": "inhibits",
      "evidence_text": "Novel compound with potent antagonistic activity against orexin receptors may be new treatment option for patients with insomnia",
      "confidence": 0.9,
      "pmid": "35296912"
    },
    {
      "entity1": "TS-142",
      "entity2": "OX2R",
      "relationship": "inhibits",
      "evidence_text": "Novel compound with potent antagonistic activity against orexin receptors may be new treatment option for patients with insomnia",
      "confidence": 0.9,
      "pmid": "35296912"
    },
    {
      "entity1": "orexin-A",
      "entity2": "analgesia",
      "relationship": "activates",
      "evidence_text": "orexin peptides induce analgesia that is comparable to morphine",
      "confidence": 0.9,
      "pmid": "28552056"
    },
    {
      "entity1": "SDM-878",
      "entity2": "OX2R",
      "relationship": "inhibits",
      "evidence_text": "SDM-878 showed potent inhibitory activities for human and rat OX",
      "confidence": 0.95,
      "pmid": "32337858"
    },
    {
      "entity1": "ZGW",
      "entity2": "OX1R",
      "relationship": "inhibits",
      "evidence_text": "while downregulated for the OX1R mRNA and protein expression",
      "confidence": 0.9,
      "pmid": "34939389"
    },
    {
      "entity1": "(S)-1-amino-tetralin derivative",
      "entity2": "OX2R",
      "relationship": "activates",
      "evidence_text": "(-)-6 having a (S)-1-amino-tetralin skeleton showed a OX",
      "confidence": 0.9,
      "pmid": "35051577"
    },
    {
      "entity1": "OX1R antagonist",
      "entity2": "drug addiction",
      "relationship": "inhibits",
      "evidence_text": "Blockade of the orexin-1 receptor has been suggested as a potential strategy for the treatment of drug addiction",
      "confidence": 0.85,
      "pmid": "29129052"
    },
    {
      "entity1": "sleep improvement",
      "entity2": "seizures",
      "relationship": "inhibits",
      "evidence_text": "Accordingly, sleep improvement can be a therapeutic strategy for reducing seizures and better managing epilepsy.",
      "confidence": 0.9,
      "pmid": "37212716"
    },
    {
      "entity1": "DORAs",
      "entity2": "sleep impairment",
      "relationship": "regulates",
      "evidence_text": "the recently approved dual orexin receptor antagonists (DORAs) have been suggested for treating sleep impairment and insomnia in PWE.",
      "confidence": 0.9,
      "pmid": "37212716"
    },
    {
      "entity1": "DORAs",
      "entity2": "epilepsy",
      "relationship": "inhibits",
      "evidence_text": "the antagonism to the orexin system by DORAs can improve epilepsy by both a direct and a sleep-mediated (indirect) effect.",
      "confidence": 0.9,
      "pmid": "37212716"
    },
    {
      "entity1": "orexin-B",
      "entity2": "contractile shortening",
      "relationship": "activates",
      "evidence_text": "In isolated rat cardiomyocytes, only orexin-B (OR-B) caused an increase in contractile shortening, independent of diastolic or systolic calcium levels.",
      "confidence": 0.9,
      "pmid": "30467191"
    },
    {
      "entity1": "MK-1064",
      "entity2": "SWS onset",
      "relationship": "activates",
      "evidence_text": "Acute MK-1064 hastened SWS onset and increased the number of SWS episodes, without increasing sleep fragmentation in AIE and controls.",
      "confidence": 0.9,
      "pmid": "32424852"
    },
    {
      "entity1": "MK-1064",
      "entity2": "SWS episodes",
      "relationship": "activates",
      "evidence_text": "Acute MK-1064 hastened SWS onset and increased the number of SWS episodes, without increasing sleep fragmentation in AIE and controls.",
      "confidence": 0.9,
      "pmid": "32424852"
    }
  ],
  "validation_results": [
    {
      "relationship": {
        "entity1": "Almorexant",
        "entity2": "orexin system",
        "relationship": "inhibits",
        "evidence_text": "Almorexant is now mainly used as a commercial specific inhibitor of the orexin system in animal studies due to safety issues.",
        "confidence": 0.9,
        "pmid": "35972717"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin-A",
        "entity2": "HCRTR1",
        "relationship": "binds_to",
        "evidence_text": "the hypocretins/orexins are two excitatory neuropeptides... that are the endogenous ligands for two G-protein-coupled receptors, HCRTR1/OX1R and HCRTR2/OX2R.",
        "confidence": 1.0,
        "pmid": "34052813"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 0.8279569892473119,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin-A",
        "entity2": "HCRTR2",
        "relationship": "binds_to",
        "evidence_text": "the hypocretins/orexins are two excitatory neuropeptides... that are the endogenous ligands for two G-protein-coupled receptors, HCRTR1/OX1R and HCRTR2/OX2R.",
        "confidence": 1.0,
        "pmid": "34052813"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 0.8279569892473119,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "orexin system",
        "entity2": "Alzheimer's disease",
        "relationship": "associated_with",
        "evidence_text": "Dysregulation of the orexin system occurs in aging and AD, positioning ORAs as advantageous for these populations.",
        "confidence": 0.8,
        "pmid": "37708433"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "orexin system",
        "entity2": "Alzheimer's disease",
        "relationship": "associated_with",
        "evidence_text": "Given the high prevalence of sleep disturbances in Alzheimer's disease (AD) and their reported involvement in AD pathophysiology, the orexin system is hypothesized to contribute to the disease pathogenesis.",
        "confidence": 0.85,
        "pmid": "39365407"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "SORA1",
        "entity2": "anxiety",
        "relationship": "regulates",
        "evidence_text": "SORA1 may be promising for the treatment of anxiety and drug addiction.",
        "confidence": 0.7,
        "pmid": "31782044"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.6042553191489362,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.60): 'SORA1 may be promising for the treatment of anxiety and drug addiction....'"
    },
    {
      "relationship": {
        "entity1": "Orexin-A",
        "entity2": "HCRTR1",
        "relationship": "inhibits",
        "evidence_text": "Overall, it was concluded that OXA exerts neuroprotective effect ... by Inhibiting OX1R-mediated NF-\u03baB, MAPK/ERK and MAPK/p38 signaling pathways.",
        "confidence": 0.95,
        "pmid": "34358627"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 0.7012345679012346,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin-A",
        "entity2": "NF-\u03baB",
        "relationship": "inhibits",
        "evidence_text": "Overall, it was concluded that OXA exerts neuroprotective effect ... by Inhibiting OX1R-mediated NF-\u03baB, MAPK/ERK and MAPK/p38 signaling pathways.",
        "confidence": 0.9,
        "pmid": "34358627"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 0.7012345679012346,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "TAK-861",
        "entity2": "OX2R",
        "relationship": "activates",
        "evidence_text": "TAK-861 ... activates OX2R with a half-maximal effective concentration of 2.5\u00a0nM.",
        "confidence": 0.98,
        "pmid": "39242684"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.3675675675675676,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.37): 'TAK-861 ... activates OX2R with a half-maximal effective concentration of 2.5\u00a0nM....'"
    },
    {
      "relationship": {
        "entity1": "TAK-994",
        "entity2": "OX2R",
        "relationship": "activates",
        "evidence_text": "TAK-994, an oral orexin receptor 2-selective agonist, in patients with narcolepsy type 1.",
        "confidence": 0.95,
        "pmid": "37494485"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "MSZRD",
        "entity2": "Orexin-A",
        "relationship": "inhibits",
        "evidence_text": "MSZRD significantly downregulated the serum Orexin-A content in insomnia mice.",
        "confidence": 0.9,
        "pmid": "34509822"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 0.861878453038674,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "MSZRD",
        "entity2": "OX2R",
        "relationship": "inhibits",
        "evidence_text": "MSZRD significantly downregulated ... hypothalamic OX2R expression.",
        "confidence": 0.9,
        "pmid": "34509822"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.5546218487394958,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.55): 'MSZRD significantly downregulated ... hypothalamic OX2R expression....'"
    },
    {
      "relationship": {
        "entity1": "almorexant",
        "entity2": "orexin receptors",
        "relationship": "inhibits",
        "evidence_text": "injected intraperitoneally with almorexant, a dual orexin receptor antagonist (DORA)",
        "confidence": 0.95,
        "pmid": "39047304"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "almorexant",
        "entity2": "A\u03b2 deposition",
        "relationship": "inhibits",
        "evidence_text": "The application of almorexant can increase the total sleep time of sleep-deprived mice and reduce cognitive impairment and A\u03b2 deposition",
        "confidence": 0.92,
        "pmid": "39047304"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "almorexant",
        "entity2": "Aquaporin-4 polarity",
        "relationship": "associated_with",
        "evidence_text": "which is related to the improvement in Aquaporin-4 polarity",
        "confidence": 0.85,
        "pmid": "39047304"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "sleep deprivation",
        "entity2": "A\u03b2 deposition",
        "relationship": "activates",
        "evidence_text": "sleep deprivation aggravated learning and memory impairment and increased brain \u03b2-amyloid (A\u03b2) deposition in mice with AD",
        "confidence": 0.9,
        "pmid": "39047304"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "orexin",
        "entity2": "OX1R",
        "relationship": "activates",
        "evidence_text": "Orexins ... bind and activating two G-protein-coupled receptors (GPCRs), orexin receptor type 1 (OX1R) and type 2 (OX2R)",
        "confidence": 0.96,
        "pmid": "30002617"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 0.8698884758364313,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "orexin",
        "entity2": "OX2R",
        "relationship": "activates",
        "evidence_text": "Orexins ... bind and activating two G-protein-coupled receptors (GPCRs), orexin receptor type 1 (OX1R) and type 2 (OX2R)",
        "confidence": 0.96,
        "pmid": "30002617"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 0.8698884758364313,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "orexin",
        "entity2": "OX1R",
        "relationship": "activates",
        "evidence_text": "Orexin enhances learning and memory as well as reward, stress, seizures, and epilepsy, partly through OX1Rs",
        "confidence": 0.88,
        "pmid": "35180935"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "5-HT1AR",
        "entity2": "OX1R",
        "relationship": "binds_to",
        "evidence_text": "5-HT1AR and OX1R form constitutive heterodimers",
        "confidence": 0.94,
        "pmid": "35338110"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "orexin system",
        "entity2": "hypertension",
        "relationship": "activates",
        "evidence_text": "hyperactivity of the orexin system contributes to hypertension",
        "confidence": 0.9,
        "pmid": "28349223"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "20d",
        "entity2": "OX2R",
        "relationship": "activates",
        "evidence_text": "20d and 28d showed full agonist activity against OX",
        "confidence": 0.89,
        "pmid": "36690040"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "28d",
        "entity2": "OX2R",
        "relationship": "activates",
        "evidence_text": "20d and 28d showed full agonist activity against OX",
        "confidence": 0.89,
        "pmid": "36690040"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "ORN0829",
        "entity2": "OX1R",
        "relationship": "inhibits",
        "evidence_text": "potent dual orexin 1/2 receptor antagonist for the treatment of insomnia",
        "confidence": 0.93,
        "pmid": "32482533"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.41711229946524064,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.42): 'potent dual orexin 1/2 receptor antagonist for the treatment of insomnia...'"
    },
    {
      "relationship": {
        "entity1": "ORN0829",
        "entity2": "OX2R",
        "relationship": "inhibits",
        "evidence_text": "potent dual orexin 1/2 receptor antagonist for the treatment of insomnia",
        "confidence": 0.93,
        "pmid": "32482533"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.41711229946524064,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.42): 'potent dual orexin 1/2 receptor antagonist for the treatment of insomnia...'"
    },
    {
      "relationship": {
        "entity1": "OX2R antagonist",
        "entity2": "OX2R",
        "relationship": "inhibits",
        "evidence_text": "dual orexin receptor antagonist suvorexant",
        "confidence": 0.9,
        "pmid": "37553894"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "OX2R antagonist",
        "entity2": "cognitive performance",
        "relationship": "associated_with",
        "evidence_text": "Orexin 2 receptor antagonism ... improves ... cognitive performance in tau transgenic mice",
        "confidence": 0.88,
        "pmid": "37553894"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.36065573770491804,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.36): 'Orexin 2 receptor antagonism ... improves ... cognitive performance in tau transgenic mice...'"
    },
    {
      "relationship": {
        "entity1": "OXA",
        "entity2": "OX1R",
        "relationship": "binds_to",
        "evidence_text": "Both OXA and OXB peptides bind to two G-coupled receptors, orexin-1 (OX1R) and orexin-2 (OX2R) receptor, though with different binding affinity.",
        "confidence": 0.96,
        "pmid": "29496265"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "OXA",
        "entity2": "OX2R",
        "relationship": "binds_to",
        "evidence_text": "Both OXA and OXB peptides bind to two G-coupled receptors, orexin-1 (OX1R) and orexin-2 (OX2R) receptor, though with different binding affinity.",
        "confidence": 0.96,
        "pmid": "29496265"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "OXB",
        "entity2": "OX1R",
        "relationship": "binds_to",
        "evidence_text": "Both OXA and OXB peptides bind to two G-coupled receptors, orexin-1 (OX1R) and orexin-2 (OX2R) receptor, though with different binding affinity.",
        "confidence": 0.96,
        "pmid": "29496265"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "OXB",
        "entity2": "OX2R",
        "relationship": "binds_to",
        "evidence_text": "Both OXA and OXB peptides bind to two G-coupled receptors, orexin-1 (OX1R) and orexin-2 (OX2R) receptor, though with different binding affinity.",
        "confidence": 0.96,
        "pmid": "29496265"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "OXB",
        "entity2": "OX2R",
        "relationship": "cooccurs_with",
        "evidence_text": "Immunohistochemical staining of sections from caput, corpus and cauda segments of the organ showed intense signals for both OXB and OX2R in the principal cells of the lining epithelium.",
        "confidence": 0.92,
        "pmid": "29496265"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 0.8685446009389671,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "fear expression",
        "relationship": "inhibits",
        "evidence_text": "dual orexin receptor antagonists (DORAs) inhibit fear acquisition and expression.",
        "confidence": 0.94,
        "pmid": "35618150"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "fear extinction",
        "relationship": "inhibits",
        "evidence_text": "Orexin activation of an infralimbic-amygdala circuit impedes fear extinction.",
        "confidence": 0.9,
        "pmid": "35618150"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 0.8235294117647058,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "startle responses",
        "relationship": "inhibits",
        "evidence_text": "Blockade of orexin receptors reduces fear\u2011conditioned startle responses.",
        "confidence": 0.93,
        "pmid": "35618150"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 0.9861111111111112,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "wakefulness",
        "relationship": "activates",
        "evidence_text": "Increased orexin activity impairs sleep by promoting wakefulness and reducing total sleep time.",
        "confidence": 0.92,
        "pmid": "35618150"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 0.7661290322580645,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "OX1R",
        "entity2": "depressive behaviors",
        "relationship": "inhibits",
        "evidence_text": "Chronic orexin-1 receptor blockage attenuates depressive behaviors.",
        "confidence": 0.94,
        "pmid": "36154849"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.36097560975609755,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.36): 'Chronic orexin-1 receptor blockage attenuates depressive behaviors....'"
    },
    {
      "relationship": {
        "entity1": "OX1R",
        "entity2": "PSD-95 expression",
        "relationship": "activates",
        "evidence_text": "Chronic orexin-1 receptor blockage ... provokes PSD-95 expression in a rat model of depression.",
        "confidence": 0.9,
        "pmid": "36154849"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.3118279569892473,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.31): 'Chronic orexin-1 receptor blockage ... provokes PSD-95 expression in a rat model of depression....'"
    },
    {
      "relationship": {
        "entity1": "OXRs",
        "entity2": "anxiety",
        "relationship": "inhibits",
        "evidence_text": "blocking of both OXRs ... impeded acute stress\u2011induced increased anxiety.",
        "confidence": 0.88,
        "pmid": "30458283"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.36363636363636365,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.36): 'blocking of both OXRs ... impeded acute stress\u2011induced increased anxiety....'"
    },
    {
      "relationship": {
        "entity1": "OX2R antagonists",
        "entity2": "wakefulness",
        "relationship": "inhibits",
        "evidence_text": "Dual and selective orexin-2 receptor antagonists have shown efficacy in inducing sleep ... by accelerating sleep onset and improving sleep efficiency and total sleep time.",
        "confidence": 0.91,
        "pmid": "34052807"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 0.8888888888888888,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "danavorexton",
        "entity2": "sleep latency",
        "relationship": "inhibits",
        "evidence_text": "danavorexton ... was associated with marked improvements in sleep latency in both NT1 and NT2.",
        "confidence": 0.95,
        "pmid": "35994639"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 0.7428571428571429,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "OX2R agonist",
        "entity2": "cataplexy-like episodes",
        "relationship": "inhibits",
        "evidence_text": "danavorexton reduced sleep/wakefulness fragmentation and cataplexy\u2011like episodes during the active phase.",
        "confidence": 0.93,
        "pmid": "35994639"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 0.8455284552845529,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "OX2R",
        "entity2": "neuronal activity",
        "relationship": "activates",
        "evidence_text": "blockade of OX2Rs ... prevented the excitatory/inhibitory changes induced by tramadol, indicating OX2R activity contributes to neuronal response.",
        "confidence": 0.89,
        "pmid": "35313383"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.43416370106761565,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.43): 'blockade of OX2Rs ... prevented the excitatory/inhibitory changes induced by tramadol, indicating OX...'"
    },
    {
      "relationship": {
        "entity1": "OXB",
        "entity2": "spermatogenesis",
        "relationship": "regulates",
        "evidence_text": "The results suggest the expression of OXB and OX2R in mouse testis and their possible regulatory role in spermatogenesis and steroidogenesis.",
        "confidence": 0.9,
        "pmid": "36841281"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "OX2R",
        "entity2": "steroidogenesis",
        "relationship": "regulates",
        "evidence_text": "The results suggest the expression of OXB and OX2R in mouse testis and their possible regulatory role in spermatogenesis and steroidogenesis.",
        "confidence": 0.9,
        "pmid": "36841281"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "sleep",
        "relationship": "regulates",
        "evidence_text": "Recent evidence suggests the central orexin system, particularly orexins A and B and their receptors, have a key regulatory role for sleep in animal and human models.",
        "confidence": 0.92,
        "pmid": "36148653"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "sympathetic activity",
        "relationship": "regulates",
        "evidence_text": "orexin system ... have a key regulatory role for ... sympathetic regulation.",
        "confidence": 0.91,
        "pmid": "36148653"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.3884297520661157,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.39): 'orexin system ... have a key regulatory role for ... sympathetic regulation....'"
    },
    {
      "relationship": {
        "entity1": "OX1R",
        "entity2": "apoptosis",
        "relationship": "activates",
        "evidence_text": "identification of OX1R expression in digestive cancers ... its ability to trigger mitochondrial apoptosis in tumoral cells.",
        "confidence": 0.88,
        "pmid": "35966051"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.2909090909090909,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.29): 'identification of OX1R expression in digestive cancers ... its ability to trigger mitochondrial apop...'"
    },
    {
      "relationship": {
        "entity1": "Orexin",
        "entity2": "blood pressure",
        "relationship": "activates",
        "evidence_text": "orexinergic stimulation results in increased blood pressure and heart rate.",
        "confidence": 0.94,
        "pmid": "29992504"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.5905511811023622,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.59): 'orexinergic stimulation results in increased blood pressure and heart rate....'"
    },
    {
      "relationship": {
        "entity1": "Orexin antagonism",
        "entity2": "blood pressure",
        "relationship": "inhibits",
        "evidence_text": "this effect may be efficiently attenuated by orexinergic antagonism.",
        "confidence": 0.9,
        "pmid": "29992504"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "TCS OX2 29",
        "entity2": "detrusor overactivity",
        "relationship": "inhibits",
        "evidence_text": "TCS ... normalizes the cystometric parameters corresponding to overactivity of the detrusor.",
        "confidence": 0.93,
        "pmid": "39402852"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.006430868167202572,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.01): 'TCS ... normalizes the cystometric parameters corresponding to overactivity of the detrusor....'"
    },
    {
      "relationship": {
        "entity1": "TCS OX2 29",
        "entity2": "depressive response",
        "relationship": "inhibits",
        "evidence_text": "TCS ... reverses the pro\u2011depressive response.",
        "confidence": 0.93,
        "pmid": "39402852"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.007575757575757576,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.01): 'TCS ... reverses the pro\u2011depressive response....'"
    },
    {
      "relationship": {
        "entity1": "OX1R",
        "entity2": "orexin A",
        "relationship": "binds_to",
        "evidence_text": "OX1R has selective affinity for orexin A.",
        "confidence": 0.95,
        "pmid": "37189339"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.4685714285714286,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.47): 'OX1R has selective affinity for orexin A....'"
    },
    {
      "relationship": {
        "entity1": "orexin",
        "entity2": "monoaminergic neurons",
        "relationship": "activates",
        "evidence_text": "Orexin neurons are thought to act primarily on monoaminergic neurons to maintain arousal and vigilance.",
        "confidence": 0.8,
        "pmid": "34052806"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "orexin",
        "entity2": "dopaminergic system",
        "relationship": "associated_with",
        "evidence_text": "Orexin also has close interactions with the dopaminergic system.",
        "confidence": 0.78,
        "pmid": "34052806"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.5161290322580645,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.52): 'Orexin also has close interactions with the dopaminergic system....'"
    },
    {
      "relationship": {
        "entity1": "hypocretin deficiency",
        "entity2": "Narcolepsy type 1",
        "relationship": "associated_with",
        "evidence_text": "Narcolepsy type 1 (NT1) ... symptoms are due to hypocretin deficiency.",
        "confidence": 0.9,
        "pmid": "39241492"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 0.7931034482758621,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "estradiol",
        "entity2": "orexin system",
        "relationship": "regulates",
        "evidence_text": "fluctuations in circulating estradiol (E2) ... alter orexin ... peptide production and receptor activity.",
        "confidence": 0.85,
        "pmid": "36571628"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.6012269938650306,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.60): 'fluctuations in circulating estradiol (E2) ... alter orexin ... peptide production and receptor acti...'"
    },
    {
      "relationship": {
        "entity1": "SB-334867",
        "entity2": "OX1R",
        "relationship": "inhibits",
        "evidence_text": "The combination of orexin-1 receptor antagonist SB-334867 and orexin-B with morphine significantly increased the analgesic effect.",
        "confidence": 0.9,
        "pmid": "36480169"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 0.7854984894259819,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "orexin-B",
        "entity2": "OX2R",
        "relationship": "activates",
        "evidence_text": "The combination of orexin-1 receptor antagonist SB-334867 and orexin-B with morphine ...",
        "confidence": 0.9,
        "pmid": "36480169"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.5951557093425606,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.60): 'The combination of orexin-1 receptor antagonist SB-334867 and orexin-B with morphine ......'"
    },
    {
      "relationship": {
        "entity1": "orexin-A",
        "entity2": "dopamine D2 receptor",
        "relationship": "activates",
        "evidence_text": "Orexin-A up-regulates dopamine D2 receptor and mRNA in the nucleus accumbens Shell.",
        "confidence": 0.95,
        "pmid": "33170427"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.4046242774566474,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.40): 'Orexin-A up-regulates dopamine D2 receptor and mRNA in the nucleus accumbens Shell....'"
    },
    {
      "relationship": {
        "entity1": "OX2R",
        "entity2": "ERK1/2",
        "relationship": "activates",
        "evidence_text": "These mutants exhibited decreased phosphorylation levels of ERK1/2 ... compared with wild-type pOX2R.",
        "confidence": 0.85,
        "pmid": "32296386"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 0.8132780082987552,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "OX2R",
        "entity2": "p38",
        "relationship": "activates",
        "evidence_text": "These mutants exhibited decreased phosphorylation levels of ... p38 ... compared with wild-type pOX2R.",
        "confidence": 0.85,
        "pmid": "32296386"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 0.7933884297520661,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "OX2R",
        "entity2": "CREB",
        "relationship": "activates",
        "evidence_text": "These mutants exhibited decreased phosphorylation levels of ... CREB to some degree compared with wild-type pOX2R.",
        "confidence": 0.85,
        "pmid": "32296386"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 0.8740157480314961,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "OX2R",
        "entity2": "amyloid \u03b2 (A\u03b2)",
        "relationship": "inhibits",
        "evidence_text": "OX2R blockade ... reduced A\u03b2 pathology ... in 3xTg-AD mice.",
        "confidence": 0.9,
        "pmid": "38682858"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.3333333333333333,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.33): 'OX2R blockade ... reduced A\u03b2 pathology ... in 3xTg-AD mice....'"
    },
    {
      "relationship": {
        "entity1": "OX2R",
        "entity2": "tau phosphorylation",
        "relationship": "inhibits",
        "evidence_text": "OX2R blockade ... reduced ... tau phosphorylation ... in 3xTg-AD mice.",
        "confidence": 0.9,
        "pmid": "38682858"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.33548387096774196,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.34): 'OX2R blockade ... reduced ... tau phosphorylation ... in 3xTg-AD mice....'"
    },
    {
      "relationship": {
        "entity1": "OX2R",
        "entity2": "neuroinflammation",
        "relationship": "inhibits",
        "evidence_text": "OX2R blockade ... alleviated ... neuroinflammation in 3xTg-AD mice.",
        "confidence": 0.9,
        "pmid": "38682858"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.3026315789473684,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.30): 'OX2R blockade ... alleviated ... neuroinflammation in 3xTg-AD mice....'"
    },
    {
      "relationship": {
        "entity1": "lemborexant",
        "entity2": "OX1R",
        "relationship": "inhibits",
        "evidence_text": "Lemborexant is a dual antagonist acting on both two orexin receptors, the orexin 1 (OX1R) and 2 receptor (OX2R), with stronger inhibitory effects on OX2R.",
        "confidence": 0.9,
        "pmid": "33642529"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "lemborexant",
        "entity2": "OX2R",
        "relationship": "inhibits",
        "evidence_text": "Lemborexant is a dual antagonist ... with stronger inhibitory effects on OX2R.",
        "confidence": 0.9,
        "pmid": "33642529"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.646551724137931,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.65): 'Lemborexant is a dual antagonist ... with stronger inhibitory effects on OX2R....'"
    },
    {
      "relationship": {
        "entity1": "hyper-activation of orexin system",
        "entity2": "insomnia",
        "relationship": "associated_with",
        "evidence_text": "Hyper-activation of the orexin system also causes sleep disturbances, such as insomnia, and hence, suvorexant ... has been clinically used to treat insomnia.",
        "confidence": 0.85,
        "pmid": "29289556"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 0.9005847953216374,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "suvorexant",
        "entity2": "orexin receptors",
        "relationship": "inhibits",
        "evidence_text": "suvorexant, an orexin receptor antagonist, has been clinically used to treat insomnia.",
        "confidence": 0.88,
        "pmid": "29289556"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "CVN766",
        "entity2": "OX1R",
        "relationship": "inhibits",
        "evidence_text": "CVN766, a potent orexin 1 receptor antagonist that has greater than 1000-fold selectivity for the orexin 1 receptor over the orexin 2 receptor.",
        "confidence": 0.95,
        "pmid": "38295907"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 0.7506561679790026,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "orexin B",
        "entity2": "OX2R",
        "relationship": "activates",
        "evidence_text": "Supradural orexin B induced migraine-like pain behaviors ... increased TNC ERK phosphorylation exclusively in males.",
        "confidence": 0.92,
        "pmid": "39233656"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 0.889763779527559,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "OX2R",
        "entity2": "ERK phosphorylation",
        "relationship": "activates",
        "evidence_text": "Supradural orexin B induced ... increased TNC ERK phosphorylation ... OX2R expression was higher in male TG.",
        "confidence": 0.9,
        "pmid": "39233656"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.6260162601626016,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.63): 'Supradural orexin B induced ... increased TNC ERK phosphorylation ... OX2R expression was higher in ...'"
    },
    {
      "relationship": {
        "entity1": "suvorexant",
        "entity2": "orexin signaling",
        "relationship": "inhibits",
        "evidence_text": "Blockade of orexin signaling with supradural suvorexant, a dual orexin receptor antagonist, prevented ... migraine-like pain in males.",
        "confidence": 0.88,
        "pmid": "39233656"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 0.81875,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "OxR1",
        "entity2": "odor-attractive behavior",
        "relationship": "activates",
        "evidence_text": "When odor-food reward associated mice underwent OxR1 antagonist injection in the amOT, their odor-attractive behavior was suppressed.",
        "confidence": 0.85,
        "pmid": "39725686"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 0.8417721518987342,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "OxR1",
        "entity2": "odor-aversive behavior",
        "relationship": "inhibits",
        "evidence_text": "OxR1 antagonist injection ... odor-aversive behavior was conversely induced.",
        "confidence": 0.85,
        "pmid": "39725686"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.5637065637065637,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.56): 'OxR1 antagonist injection ... odor-aversive behavior was conversely induced....'"
    },
    {
      "relationship": {
        "entity1": "hypocretin/orexin",
        "entity2": "cocaine abuse",
        "relationship": "activates",
        "evidence_text": "blocking hcrt/ox transmission using systemic or site-directed pharmacological antagonists markedly reduced motivated drug-taking as well as drug-seeking",
        "confidence": 0.9,
        "pmid": "30796894"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "OX2R",
        "entity2": "5-HT1AR",
        "relationship": "binds_to",
        "evidence_text": "we firstly demonstrated the heterodimer formation of 5-HT1AR and OX2R",
        "confidence": 0.95,
        "pmid": "30481562"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "OX2R",
        "entity2": "ERK",
        "relationship": "inhibits",
        "evidence_text": "western blotting data showed that 5-HT1AR and OX2R heterodimer decreased the levels of phosphorylation of extracellular signal-regulated kinase (ERK)",
        "confidence": 0.9,
        "pmid": "30481562"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "OX2R",
        "entity2": "CREB",
        "relationship": "inhibits",
        "evidence_text": "western blotting data showed that 5-HT1AR and OX2R heterodimer decreased the levels of phosphorylation of ... cAMP-response element-binding protein (CREB)",
        "confidence": 0.9,
        "pmid": "30481562"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 0.825136612021858,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "Danavorexton",
        "entity2": "OX2R",
        "relationship": "activates",
        "evidence_text": "Danavorexton (TAK-925) is an agonist for orexin receptor 2 where it promotes recovery from inhalational and i.v. anaesthesia and opioid sedation",
        "confidence": 0.95,
        "pmid": "38346840"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "TS-142",
        "entity2": "OX1R",
        "relationship": "inhibits",
        "evidence_text": "Novel compound with potent antagonistic activity against orexin receptors may be new treatment option for patients with insomnia",
        "confidence": 0.9,
        "pmid": "35296912"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "TS-142",
        "entity2": "OX2R",
        "relationship": "inhibits",
        "evidence_text": "Novel compound with potent antagonistic activity against orexin receptors may be new treatment option for patients with insomnia",
        "confidence": 0.9,
        "pmid": "35296912"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "orexin-A",
        "entity2": "analgesia",
        "relationship": "activates",
        "evidence_text": "orexin peptides induce analgesia that is comparable to morphine",
        "confidence": 0.9,
        "pmid": "28552056"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "orexin-B",
        "entity2": "subthalamic nucleus neurons",
        "relationship": "activates",
        "evidence_text": "The subthalamic neurons are activated by both orexin-A and orexin-B",
        "confidence": 0.95,
        "pmid": "29138106"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.430622009569378,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.43): 'The subthalamic neurons are activated by both orexin-A and orexin-B...'"
    },
    {
      "relationship": {
        "entity1": "orexin-A",
        "entity2": "subthalamic nucleus neurons",
        "relationship": "activates",
        "evidence_text": "The subthalamic neurons are activated by both orexin-A and orexin-B",
        "confidence": 0.95,
        "pmid": "29138106"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.430622009569378,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.43): 'The subthalamic neurons are activated by both orexin-A and orexin-B...'"
    },
    {
      "relationship": {
        "entity1": "SDM-878",
        "entity2": "OX2R",
        "relationship": "inhibits",
        "evidence_text": "SDM-878 showed potent inhibitory activities for human and rat OX",
        "confidence": 0.95,
        "pmid": "32337858"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "OX2R",
        "entity2": "resilience",
        "relationship": "activates",
        "evidence_text": "Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression",
        "confidence": 0.9,
        "pmid": "30240784"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.22340425531914893,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.22): 'Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility...'"
    },
    {
      "relationship": {
        "entity1": "OX2R",
        "entity2": "susceptibility to stress, anxiety and depression",
        "relationship": "inhibits",
        "evidence_text": "Orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression",
        "confidence": 0.9,
        "pmid": "30240784"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.2900763358778626,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.29): 'Orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression...'"
    },
    {
      "relationship": {
        "entity1": "OX2R",
        "entity2": "myocardial protection",
        "relationship": "activates",
        "evidence_text": "Role of Orexin-B/Orexin 2 receptor in myocardial protection",
        "confidence": 0.9,
        "pmid": "30948623"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.3546099290780142,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.35): 'Role of Orexin-B/Orexin 2 receptor in myocardial protection...'"
    },
    {
      "relationship": {
        "entity1": "TAK-925",
        "entity2": "HCRTR2",
        "relationship": "activates",
        "evidence_text": "TAK-925 (1-10 mg/kg, s.c.) and ARN-776 (1-10 mg/kg, i.p.) were injected ...",
        "confidence": 0.95,
        "pmid": "36808670"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.5384615384615384,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.54): 'TAK-925 (1-10 mg/kg, s.c.) and ARN-776 (1-10 mg/kg, i.p.) were injected ......'"
    },
    {
      "relationship": {
        "entity1": "ARN-776",
        "entity2": "HCRTR2",
        "relationship": "activates",
        "evidence_text": "TAK-925 (1-10 mg/kg, s.c.) and ARN-776 (1-10 mg/kg, i.p.) were injected ...",
        "confidence": 0.95,
        "pmid": "36808670"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.5384615384615384,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.54): 'TAK-925 (1-10 mg/kg, s.c.) and ARN-776 (1-10 mg/kg, i.p.) were injected ......'"
    },
    {
      "relationship": {
        "entity1": "OX2R",
        "entity2": "Na+/Ca2+ exchanger",
        "relationship": "activates",
        "evidence_text": "the main acute downstream responses of OXR activation are ... the activation of the Na+/Ca2+ exchanger",
        "confidence": 0.9,
        "pmid": "34052812"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.5792682926829268,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.58): 'the main acute downstream responses of OXR activation are ... the activation of the Na+/Ca2+ exchang...'"
    },
    {
      "relationship": {
        "entity1": "OX2R",
        "entity2": "2-arachidonoyl glycerol",
        "relationship": "activates",
        "evidence_text": "may also ... lead to the production of the potent endocannabinoid (eCB), 2-arachidonoyl glycerol",
        "confidence": 0.9,
        "pmid": "34052812"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.5194029850746269,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.52): 'may also ... lead to the production of the potent endocannabinoid (eCB), 2-arachidonoyl glycerol...'"
    },
    {
      "relationship": {
        "entity1": "ZGW",
        "entity2": "orexin-A",
        "relationship": "activates",
        "evidence_text": "it was upregulated for the orexin-A ... expression from the hypothalamus and tibiae",
        "confidence": 0.9,
        "pmid": "34939389"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.6197183098591549,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.62): 'it was upregulated for the orexin-A ... expression from the hypothalamus and tibiae...'"
    },
    {
      "relationship": {
        "entity1": "ZGW",
        "entity2": "OX2R",
        "relationship": "activates",
        "evidence_text": "it was upregulated for the ... OX2R mRNA or protein expression",
        "confidence": 0.9,
        "pmid": "34939389"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.5104166666666666,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.51): 'it was upregulated for the ... OX2R mRNA or protein expression...'"
    },
    {
      "relationship": {
        "entity1": "ZGW",
        "entity2": "OX1R",
        "relationship": "inhibits",
        "evidence_text": "while downregulated for the OX1R mRNA and protein expression",
        "confidence": 0.9,
        "pmid": "34939389"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "(S)-1-amino-tetralin derivative",
        "entity2": "OX2R",
        "relationship": "activates",
        "evidence_text": "(-)-6 having a (S)-1-amino-tetralin skeleton showed a OX",
        "confidence": 0.9,
        "pmid": "35051577"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "OX1R antagonist",
        "entity2": "drug addiction",
        "relationship": "inhibits",
        "evidence_text": "Blockade of the orexin-1 receptor has been suggested as a potential strategy for the treatment of drug addiction",
        "confidence": 0.85,
        "pmid": "29129052"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "HCRTR2",
        "entity2": "hyperarousal",
        "relationship": "inhibits",
        "evidence_text": "loss of Hcrtr2 ... induced a dramatic increase in theta ... hyperarousal",
        "confidence": 0.9,
        "pmid": "38123729"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.11029411764705882,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.11): 'loss of Hcrtr2 ... induced a dramatic increase in theta ... hyperarousal...'"
    },
    {
      "relationship": {
        "entity1": "sleep improvement",
        "entity2": "seizures",
        "relationship": "inhibits",
        "evidence_text": "Accordingly, sleep improvement can be a therapeutic strategy for reducing seizures and better managing epilepsy.",
        "confidence": 0.9,
        "pmid": "37212716"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "DORAs",
        "entity2": "sleep impairment",
        "relationship": "regulates",
        "evidence_text": "the recently approved dual orexin receptor antagonists (DORAs) have been suggested for treating sleep impairment and insomnia in PWE.",
        "confidence": 0.9,
        "pmid": "37212716"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "DORAs",
        "entity2": "epilepsy",
        "relationship": "inhibits",
        "evidence_text": "the antagonism to the orexin system by DORAs can improve epilepsy by both a direct and a sleep-mediated (indirect) effect.",
        "confidence": 0.9,
        "pmid": "37212716"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "orexin-B",
        "entity2": "contractile shortening",
        "relationship": "activates",
        "evidence_text": "In isolated rat cardiomyocytes, only orexin-B (OR-B) caused an increase in contractile shortening, independent of diastolic or systolic calcium levels.",
        "confidence": 0.9,
        "pmid": "30467191"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "MK-1064",
        "entity2": "SWS onset",
        "relationship": "activates",
        "evidence_text": "Acute MK-1064 hastened SWS onset and increased the number of SWS episodes, without increasing sleep fragmentation in AIE and controls.",
        "confidence": 0.9,
        "pmid": "32424852"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "MK-1064",
        "entity2": "SWS episodes",
        "relationship": "activates",
        "evidence_text": "Acute MK-1064 hastened SWS onset and increased the number of SWS episodes, without increasing sleep fragmentation in AIE and controls.",
        "confidence": 0.9,
        "pmid": "32424852"
      },
      "pmid_valid": true,
      "evidence_valid": true,
      "evidence_similarity": 1.0,
      "is_valid": true,
      "error_message": null
    },
    {
      "relationship": {
        "entity1": "AIE",
        "entity2": "fragmentation of slow wave sleep",
        "relationship": "associated_with",
        "evidence_text": "Female AIE rats exhibited lasting changes in sleep compared to controls. This was demonstrated by increased fragmentation of slow wave sleep (SWS) and rapid eye movement sleep.",
        "confidence": 0.9,
        "pmid": "32424852"
      },
      "pmid_valid": true,
      "evidence_valid": false,
      "evidence_similarity": 0.6094674556213018,
      "is_valid": false,
      "error_message": "Evidence not found in abstract (similarity: 0.61): 'Female AIE rats exhibited lasting changes in sleep compared to controls. This was demonstrated by in...'"
    }
  ],
  "statistics": {
    "total_abstracts": 100,
    "total_chunks": 6,
    "chunks_processed": 6,
    "total_relationships": 107,
    "valid_relationships": 68,
    "invalid_relationships": 39,
    "pmid_failures": 0,
    "evidence_failures": 39,
    "validation_rate": 0.6355140186915887,
    "total_prompt_tokens": 32383,
    "total_completion_tokens": 20233,
    "total_latency_ms": 17487.19048500061,
    "wall_clock_ms": 4387.925863265991,
    "throughput_tok_per_sec": 3008.8309522979475
  },
  "errors": []
}